Michal L Melamed1, Erin D Michos, Wendy Post, Brad Astor. 1. Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave, Ullmann 615, Bronx, NY 10461, USA. mmelamed@aecom.yu.edu
Abstract
BACKGROUND: In patients undergoing dialysis, therapy with calcitriol or paricalcitol or other vitamin D agents is associated with reduced mortality. Observational data suggests that low 25-hydroxyvitamin D levels (25[OH]D) are associated with diabetes mellitus, hypertension, and cancers. However, whether low serum 25(OH)D levels are associated with mortality in the general population is unknown. METHODS: We tested the association of low 25(OH)D levels with all-cause, cancer, and cardiovascular disease (CVD) mortality in 13 331 nationally representative adults 20 years or older from the Third National Health and Nutrition Examination Survey (NHANES III) linked mortality files. Participant vitamin D levels were collected from 1988 through 1994, and individuals were passively followed for mortality through 2000. RESULTS: In cross-sectional multivariate analyses, increasing age, female sex, nonwhite race/ethnicity, diabetes, current smoking, and higher body mass index were all independently associated with higher odds of 25(OH)D deficiency (lowest quartile of 25(OH)D level, <17.8 ng/mL [to convert to nanomoles per liter, multiply by 2.496]), while greater physical activity, vitamin D supplementation, and nonwinter season were inversely associated. During a median 8.7 years of follow-up, there were 1806 deaths, including 777 from CVD. In multivariate models (adjusted for baseline demographics, season, and traditional and novel CVD risk factors), compared with the highest quartile, being in the lowest quartile (25[OH]D levels <17.8 ng/mL) was associated with a 26% increased rate of all-cause mortality (mortality rate ratio, 1.26; 95% CI, 1.08-1.46) and a population attributable risk of 3.1%. The adjusted models of CVD and cancer mortality revealed a higher risk, which was not statistically significant. CONCLUSION: The lowest quartile of 25(OH)D level (<17.8 ng/mL) is independently associated with all-cause mortality in the general population.
BACKGROUND: In patients undergoing dialysis, therapy with calcitriol or paricalcitol or other vitamin D agents is associated with reduced mortality. Observational data suggests that low 25-hydroxyvitamin D levels (25[OH]D) are associated with diabetes mellitus, hypertension, and cancers. However, whether low serum 25(OH)D levels are associated with mortality in the general population is unknown. METHODS: We tested the association of low 25(OH)D levels with all-cause, cancer, and cardiovascular disease (CVD) mortality in 13 331 nationally representative adults 20 years or older from the Third National Health and Nutrition Examination Survey (NHANES III) linked mortality files. Participantvitamin D levels were collected from 1988 through 1994, and individuals were passively followed for mortality through 2000. RESULTS: In cross-sectional multivariate analyses, increasing age, female sex, nonwhite race/ethnicity, diabetes, current smoking, and higher body mass index were all independently associated with higher odds of 25(OH)D deficiency (lowest quartile of 25(OH)D level, <17.8 ng/mL [to convert to nanomoles per liter, multiply by 2.496]), while greater physical activity, vitamin D supplementation, and nonwinter season were inversely associated. During a median 8.7 years of follow-up, there were 1806 deaths, including 777 from CVD. In multivariate models (adjusted for baseline demographics, season, and traditional and novel CVD risk factors), compared with the highest quartile, being in the lowest quartile (25[OH]D levels <17.8 ng/mL) was associated with a 26% increased rate of all-cause mortality (mortality rate ratio, 1.26; 95% CI, 1.08-1.46) and a population attributable risk of 3.1%. The adjusted models of CVD and cancer mortality revealed a higher risk, which was not statistically significant. CONCLUSION: The lowest quartile of 25(OH)D level (<17.8 ng/mL) is independently associated with all-cause mortality in the general population.
Authors: Heike A Bischoff-Ferrari; Edward Giovannucci; Walter C Willett; Thomas Dietrich; Bess Dawson-Hughes Journal: Am J Clin Nutr Date: 2006-07 Impact factor: 7.045
Authors: Anastassios G Pittas; Bess Dawson-Hughes; Tricia Li; Rob M Van Dam; Walter C Willett; Joann E Manson; Frank B Hu Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Yong Gil Hwang; Hui-Chen Hsu; Fei-Chu Lim; Qi Wu; PingAr Yang; Gordon Fisher; Gary R Hunter; John D Mountz Journal: Adv Aging Res Date: 2013-05
Authors: Kathleen J Motil; Judy O Barrish; Jane Lane; Suzanne P Geerts; Fran Annese; Lauren McNair; Alan K Percy; Steven A Skinner; Jeffrey L Neul; Daniel G Glaze Journal: J Pediatr Gastroenterol Nutr Date: 2011-11 Impact factor: 2.839
Authors: Bryan Kestenbaum; Ronit Katz; Ian de Boer; Andy Hoofnagle; Mark J Sarnak; Michael G Shlipak; Nancy S Jenny; David S Siscovick Journal: J Am Coll Cardiol Date: 2011-09-27 Impact factor: 24.094
Authors: Amy D Proal; Paul J Albert; Greg P Blaney; Inge A Lindseth; Chris Benediktsson; Trevor G Marshall Journal: Cell Mol Immunol Date: 2011-01-31 Impact factor: 11.530
Authors: Marcella D Walker; Elaine Cong; Anna Kepley; Marco R Di Tullio; Tatjana Rundek; Shunichi Homma; James A Lee; Rui Liu; Polly Young; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg Journal: J Clin Endocrinol Metab Date: 2013-11-27 Impact factor: 5.958
Authors: Chris Morgan; Andreas Kyvernitakis; Roy Cho; Orestis Pappas; Karthikeyan Ranganathan; Michael R Fischer; Venkatraman Srinivasan Journal: Am J Cardiovasc Dis Date: 2018-04-05